key: cord-0813277-qfwj1l6c
authors: Alkhateeb, Khaled J.; Cahill, Meredith N.; Ross, Adam S.; Arnold, Forest W.; Snyder, James W.
title: The reliability of saliva for the detection of SARS-CoV-2 in symptomatic and asymptomatic patients: Insights on the diagnostic performance and utility for COVID-19 screening
date: 2021-06-06
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115450
sha: e0c0a9f230717b4e455925bccbadaec7d8326edd
doc_id: 813277
cord_uid: qfwj1l6c

Current literature has focused on testing saliva in symptomatic patients, and little information is available regarding saliva performance in asymptomatic SARS-CoV-2 infection. We compared paired saliva and nasopharyngeal swabs (NPS) collected from 33 symptomatic and 12 asymptomatic known SARS-CoV-2-positive patients. Saliva had an overall sensitivity of 59%, a specificity of 95%, and a negative predictive value of 98%. Saliva demonstrated higher sensitivity in symptomatic (80%) vs. asymptomatic individuals (36%) (P=0.006), and in high-risk (symptomatic, febrile and/or with comorbidities) (82%) vs. low-risk (asymptomatic, afebrile and no comorbidities) (22%) patients (P=0.0002). Cycle threshold (Ct) values in NPS specimens were higher in saliva-negative vs. saliva-positive cases (P= 0.02 and <0.001). Overall, these findings show that despite saliva's low sensitivity in asymptomatic SARS-CoV-2 infections, it can detect infections with lower Ct values and a potentially higher chance of viral transmission. Additional studies are warranted to fully evaluate saliva as a screening test for COVID-19.

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the causative agent of Coronavirus Disease-2019 (COVID- 19) , continues to infect thousands of people and claim thousands of lives globally on a daily basis [40] . With case numbers continuing to rise in several parts of the world, there continues to be shortages in medical resources, including specimen collection supplies (e.g., nasopharyngeal swabs, transport media) and personal protective equipment (PPE) [20, 21] . The World Health Organization (WHO) recommends the use of respiratory secretions, specifically nasopharyngeal swabs (NPS), as the specimen of choice for the detection of SARS-CoV-2 detection [7, 12] , using realtime reverse transcriptase-polymerase chain reaction (RT-PCR) [38, 39] . However, beside requiring uninterrupted supplies of swabs and transport media, NPS is an invasive and uncomfortable method requiring a trained professional for sample collection, with an increased risk of viral transmission between the patient and the individual collecting the specimen.

Saliva has been the focus of recent investigations for its utility in the diagnosis of SARS-CoV-2 infection. Testing saliva allows for self-collection in a form that has been shown to be accepted by the public [34] , limiting the risks of interactions between the public and health care workers who are frequently exposed to SARS-CoV-2, and potentially reducing the need for PPE. Saliva does not require specific collection supplies; thus, it is not affected by the frequent supply-demand imbalance. Salivary specimens have been proven to be stable in variable conditions and for a prolonged period [3, 19, 23] .

Additionally, as an inexpensive and easy-to-collect specimen type, it represents a promising candidate for point-of-care testing and mass screening of asymptomatic individuals.

Chen et al found that salivary glands express angiotensin-converting enzyme II (ACE2), the likely cell receptor for SARS-CoV-2, and identified the virus in saliva samples from patients with COVID-19 [6] .

Early reports have revealed that saliva can harbor SARS-CoV-2 and can be used to monitor viral loads [32] . Since then, several studies comparing saliva to NPS have been published, with the majority of results suggesting comparable saliva sensitivity to that of NPS [1, 2, 4, 9, 10, 17, 24, 26, [28] [29] [30] 36] . In some studies, saliva outperformed NPS in terms of sensitivity, highlighting a limitation of the latter method to be considered as the standard of care [11, 20, 42] . Such findings led the FDA to issue emergency use authorizations to Yale and Rutgers laboratories for the use of saliva as a sample for SARS-CoV-2 testing in symptomatic individuals suspected of COVID-19 [27, 43] .

With the majority of studies on saliva being performed on confirmed infections or symptomatic patients, limited literature exists on the assessment and reporting of saliva performance in asymptomatic individuals [37, 42, 44] . In this study, we evaluated the diagnostic value of saliva compared to NPS in patients presenting with symptoms suggestive of COVID-19, as well as asymptomatic SARS-CoV-2 positive patients identified as part of the institutional universal admission screening protocol.

The study was approved by the University of Louisville Institutional Review Board. All study aspects were carried out in accordance with the approved Institutional Review Board protocol (IRB# 20.0374).

All enrolled participants acknowledged understanding the aims of the study and signed a consent form prior to collection of demographics, clinical data and samples.

An infectious diseases physician selected inpatients previously determined to be positive for the virus, while eligible patients presenting to the emergency room with symptoms suggestive of COVID-19 were selected by a physician on duty. Each patient was asked if they would voluntarily provide a saliva specimen for comparative purposes following the collection of a NPS specimen which served as the comparator or "gold standard". A Patient Information Form, approved by the IRB, describing the aim of the study and the purpose of acquiring an additional specimen was given to the patient along with a collection container (sterile urine cup or a 50 conical tube) and instructions to expectorate into the collection device. We recommended 3 ml of saliva but accepted a minimum of 1 ml. Following the acquisition of a NPS, obtained by an experienced, trained healthcare provider, the swab was placed and transported in 3 ml of sterile Universal Transport Medium (UTM) (M4, Becton Dickinson, Sparks, MD; REMEL, Lenexa, KS) for SARS-CoV-2 testing, and 1 -3ml of saliva was collected. Both specimens were tested on-demand; in the event of a delay in testing, the saliva specimens were stored at 2 -8ºC and tested within 12 hours of receipt.

Symptomatic patients were those who presented to our emergency room with symptoms consistent with COVID-19, including cough, shortness of breath, dyspnea, fever, abdominal pain, diarrhea, and loss of taste or smell sensation. Patients with early-onset symptomatic infections were tested and confirmed within ≤4 days from onset of symptoms, while late-onset symptomatic infections were tested and confirmed >4 days from symptom onset. Several patients had underlying comorbidities, including hypertension, cardiovascular disease, diabetes mellitus, malignancy, asthma, COPD, HIV infection, hepatic cirrhosis and ethanol/drug abuse. A high-risk individual is someone who was either symptomatic, febrile at time of testing or had an underlying comorbidity. A low-risk individual showed no symptoms, was afebrile, and had no underlying comorbidities. Fever was chosen as a criterion separate from other symptoms because it can represent either a symptom or a sign.

If the saliva specimen was viscous, an equal volume of UTM was added to liquefy the specimen before testing. Reverse transcriptase PCR (RT-PCR) testing was performed on the DiaSorin Simplexa 

Patient characteristics were calculated for all cases. Statistical analysis was performed using R Studio Version 3.6.1. Continuous variables were reported as means with standard deviations, and categorical variables were reported as frequencies and percentages. Assessment of difference in significance for the duration of symptom onset to specimen collection between the saliva-positive and saliva-negative COVID-19 patient groups was conducted using a Chi-square test of independence. Sensitivity, specificity, negative and positive predicative values, and accuracy were calculated for saliva tests. Positive and negative predictive value calculations were based on a 5% disease prevalence. Fischer's Exact Tests and Tests of Equal Proportions were used to identify significant differences in saliva test sensitivity between 4 groups (symptomatic vs. asymptomatic; high risk vs. low risk; asymptomatic high risk vs. asymptomatic low risk; early-onset symptomatic vs. late-onset symptomatic). Significant differences in mean Ct values between concordant NPS and saliva tests for the S and ORF1ab genes were assessed using paired t-tests for 7 groups (all concordant cases, symptomatic, asymptomatic, early symptom onset, and late symptom onset). Lastly, Welch Two Sample T-tests were utilized to assess significant differences in mean Ct values between NPS and saliva tests for the S and ORF1ab genes between asymptomatic and symptomatic groups and early and late symptom onset groups, respectively. P-values less < 0.05 were used to denote significance for all tests conducted.

A total of 61 patients were screened for inclusion between the period from Apr 30, 2020 to Jun 15, 2020, of whom 48 were included (26 males and 22 females). The 13 patients excluded from the study included one patient who drank water immediately before saliva collection, three who had invalid saliva specimens on repeat testing following re-dilution in UTM and nine patients with specimens tested on a platform other than DiaSorin. The average patient age was 39.9 years (± 15.5). Clinical data were available in 45 patients. Thirty-three patients presented to our emergency room with symptoms consistent with COVID-19, and 12 were asymptomatic SARS-CoV-2 positive patients identified following universal admission screening. Patients with asymptomatic infection were admitted due to medical conditions unrelated to COVID-19 (labor and delivery, stroke, cholecystitis, psychiatric illness, syncope, and trauma). None of the asymptomatic individuals disclosed having any prior COVID-19 symptoms, recent exposure or contact with COVID-19 patients, and none of them developed symptoms during the course of their hospital stays. Comorbidities were present in 47% (21/45) of patients. Symptomatic COVID-19 cases were predominantly mild and did not require hospital admission, except one severe case requiring intubation and mechanical ventilation. Patient demographics are highlighted in Table 1 .

A total of 28 patients (58%) tested positive for the SARS-CoV-2 virus by NPS and/or saliva. NPS was positive in 27 patients versus saliva in 17 patients. The overall positive percent agreement (PPA) was 96% for NPS and 61% for saliva. One patient tested positive for SARS-CoV-2 only on a saliva sample (Table 2) . Among the SARS-CoV-2 positive symptomatic patients, the average onset of symptoms to specimen collection time was 6.3 (± 8.5) days. There was no significant difference between the time from symptom onset to specimen collection between the saliva-positive and saliva-negative COVID-19 patient groups. (Table 1) Assuming NPS as the "gold standard," saliva showed an overall sensitivity of 59% and specificity of 95%, with a negative predictive value of 98% (calculated at a prevalence of 5%). Interestingly, saliva sensitivity was 80% in the symptomatic group compared to only 36% in the asymptomatic group (P = 0.006). We then sought to stratify patients into high-risk and low-risk categories for harboring the SARS-CoV-2 virus as previously described in the methods section. Saliva showed a significantly higher sensitivity in the high-risk group (82%) compared to the low-risk group (22%) (P = 0.0002). No difference was found comparing saliva in early-onset symptomatic vs. late-onset symptomatic patients.

( Table 3) . 

In our study, saliva showed a relatively low overall sensitivity (59%) compared to NPS. Interestingly, however, the sensitivity was significantly higher in patients who were symptomatic (80%) and those who we considered being high-risk individuals (82%). These results suggest that saliva has comparable sensitivity to NPS especially in individuals with high clinical suspicion for COVID-19 and is significantly less sensitive than NPS in detecting SARS-CoV-2 in asymptomatic individuals with no known recent prior exposure and significantly higher Ct values (i.e., lower viral loads).

Evidence shows that the viral load peaks early in the course of infection (1 st week), and the duration of viral shedding can be variable, with a median of 12-20 days and lasting up to 63 days post symptom onset [41] . Higher estimated viral loads and prolonged viral shedding were found to positively correlate with disease severity and immune status [16, 41] . It was also found that asymptomatic infections and milder cases of COVID-19 have faster viral clearance than severe cases [5, 16] . These findings suggest that the course of illness, symptom development and duration of viral shedding may depend on the acquired viral inoculum and the immune status of individuals. Thus, asymptomatic infections would be suspected to generally have lower viral loads and enhanced viral clearance compared to the more severe COVID-19

cases. Furthermore, a prior study showed that saliva had lower positivity rates in asymptomatic individuals than NPS (although not statistically significant) [5] , and another study showed a higher proportion of saliva-positive tests in severe COVID-19 cases compared to mild infections [22] . Our results show a significantly lower sensitivity for saliva in asymptomatic compared to symptomatic individuals. Additionally, Ct values in saliva-negative, NPS-positive COVID-19 cases were significantly higher than those in saliva-positive, NPS-positive cases, suggesting higher viral loads in the latter. In general, we found that saliva showed higher mean Ct values than NPS in paired specimens, suggesting that the viral load in saliva is generally lower than in NPS. This difference was less evident in samples collected later in the course of infection (>4 days from symptom onset) when NPS showed the highest mean Ct values, suggesting that the viral load peaks early during infection and perhaps falls more rapidly in NPS than saliva.

Although saliva showed lower sensitivity in asymptomatic patients, our findings suggest that it can play a vital role in mass-screening for COVID-19. It is imperative to differentiate between the identification of viral RNA by RT-PCR tests and the ability to shed and transmit viable viruses. It has been shown that later in the infection (>21 days) NPS detects a significantly larger number of positive results compared to oral fluid or anterior nares specimens. At that stage of the disease, those most likely represent inactivated viral RNA shedding (false positive) with no transmission potential. This finding was observed with multiple FDA EUA molecular assays, suggesting that biological variation among specimen types, rather than the assay used for testing, is the main reason for this phenomenon [33] . Furthermore, viral cultures from patients with prolonged disease onset/ high RT-PCR Ct values failed to identify viable virus [13, 18, 35] . In one study comparing saliva to NPS, all viral culture-positive samples had concordantly positive NPS and saliva samples, and no viable virus was isolated from saliva-negative, NPS-positive patients [17] . In our study, saliva could detect patients who had lower Ct values (suggestive of higher viral loads) and likely higher risk of viral transmission. In fact, saliva was able to detect all but 2 cases with Ct values below 30, one of which had a minimum Ct value of 29.5 for one of the targets. Our findings, in conjunction with the currently available evidence, strongly suggests that saliva is sensitive enough to detect the majority of "true" active infections with potential viral transmission and have a specificity advantage over NPS by failing to detect the prolonged stage of post-disease viral RNA shedding (false positive). This ultimately gives saliva a high negative predictive value, which warrants its use especially in communities with low infection prevalence. (Supplementary Figure 1) One larger study by Yokota et al assessed saliva in the screening of predominantly asymptomatic contacts of COVID-19 patients and found comparable sensitivity to NPS [44] . Since their study predominantly included COVID-19 contacts, it may be assumed that the majority of SARS-CoV-2 positive individuals they identified had been exposed within a short period of time from testing. This was not the case in our study, as asymptomatic patients in our cohort did not disclose any prior exposure, and we simply cannot know or predict when those patients acquired the virus. Assuming faster viral clearance in asymptomatic infections as described in the literature, this explains the low saliva sensitivity in our asymptomatic cohort compared to the aforementioned study. Another recent study tested a saliva-based assay in a large cohort of asymptomatic individuals with promising results. In this study, however, saliva was compared to anterior nares/oropharyngeal swabs, not NPS [37] .

Our findings may suggest several clinical applications for saliva in the diagnosis of COVID-19. Saliva demonstrated a high sensitivity for the detection of SARS-CoV-2 in symptomatic individuals, making it a suitable specimen for the primary diagnosis of COVID-19 in that patient group, especially in the setting of swab shortage. Additionally, saliva may play a vital role in COVID-19 screening of asymptomatic individuals in different settings, such as screening individuals who are found to be febrile on temperature measurement, as well as in contact tracing campaigns, nursing home residents, teachers and students returning to schools, and airport departures. In the screening setting, saliva may prove more advantageous than NPS, as the higher sensitivity and lower specificity of the latter, particularly during the prolonged post-disease period of inactive viral RNA shedding, would lead to more false positive results that would overwhelm contact tracing programs and halt efforts of safe return to school or work.

We acknowledge several limitations to our study. Our patient cohort is small and included some who were seeking healthcare for medical conditions other than COVID-19; thus, their overall health and immune status may not reflect that of the general population. Preanalytical conditions may have played a role in testing accuracy for saliva. Although instructions were provided to health care workers and patients on optimal methods for sample collection (e.g., no food or drinking 1 hour before sample collection), the laboratory has little or no control over preanalytical factors associated with patient preparation, specimen collection, and timely transport of the specimen to the laboratory which are variables that can impact the quality of laboratory results. Unless we had prior knowledge of such factors, such as drinking within one hour before sample collection, as was learned in one case resulting in exclusion from the study, the majority of the saliva specimens that we received were accepted for testing.

With the exception of one patient, all asymptomatic patients included tested positive for SARS-CoV-2 at least on NPS, limiting the possibility of identifying false positive results. Additionally, our analysis included the overall diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value and accuracy) of saliva and NPS specimens tested primarily on a single platform (DiaSorin), with a minor subset of paired specimens tested on a second platform (Cephied GeneXpert).

However, the analysis of Ct values only included paired samples performed on a single platform (DiaSorin). Statistical analysis of Ct values was not possible on samples that were tested on a second platform since in addition to those samples being very small in number, the second platform targeted different viral genes, making comparison between the two platforms meaningless. Lastly, several studies reported varying clinical and analytical sensitivities for the DiaSorin Simplexa platform, some of which demonstrating lower sensitivity compared to other assays. [8, 14, 15, 25, 31, 45] This may potentially limit the overall reproducibility of our results across diagnostic platforms.

In conclusion, saliva demonstrates comparable sensitivity to NPS in detecting SARS-CoV-2 in symptomatic patients and those with high clinical suspicion for COVID-19. Despite showing lower overall sensitivity in asymptomatic individuals, saliva showed high specificity and negative predictive value and was able to identify asymptomatic individuals with lower Ct values (suggestive of higher viral loads) and potentially higher likelihood of SARS-CoV-2 transmission. More extensive studies conducted on a larger number of asymptomatic SARS-CoV-2-positive individuals are necessary to fully evaluate saliva's diagnostic value as a primary specimen for mass-screening for SARS -CoV-2. Table 2 . Results of parallel testing of NPS and saliva specimens across the entire cohort. Table 3 . Diagnostic test evaluation for saliva. 

Saliva is a reliable tool to detect SARS-CoV-2

Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting

Saliva collected in universal transport media is an effective, simple and highvolume amenable method to detect SARS-CoV-2

Salivary Detection of COVID-19

group OC-r (2020) The natural history and transmission potential of asymptomatic SARS-CoV-2 infection

Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2

Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2

Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim guidance

An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA

Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type

Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories

Viral dynamics in mild and severe cases of COVID-19

Variability of Salivary and Nasal Specimens for SARS-CoV-2 Detection. medRxiv

Foschino Barbaro MP (2021) Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?

Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection

Saliva Sampling and Its Direct Lysis, an Excellent Option To Increase the Number of SARS-CoV-2 Diagnostic Tests in Settings with Supply Shortages

Effective optimization of SARS-CoV-2 laboratory testing variables in an era of supply chain constraints

Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study

A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients

RT-qPCR assays based on saliva rather than on nasopharyngeal swabs are possible but should be interpreted with caution: results from a systematic review and meta-analysis

Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19

Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence

The Effect of Sample Site, Illness Duration, and the Presence of Pneumonia on the Detection of SARS-CoV-2 by Real-time Reverse Transcription PCR

Comparison of the NeuMoDX, Diasorin Simplexa, Cepheid and Roche CDC SARS-CoV 2 EUA assays using nasopharyngeal/nasal swabs in universal transport media (UTM) and sputum and tracheal aspirates

Consistent Detection of 2019 Novel Coronavirus in Saliva

Post-Disease Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares and Saliva/Oral Fluid Specimens -Significant Implications for Policy & Public Health

At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection

SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

WHO Coronavirus Disease

SARS-CoV-2: The viral shedding vs infectivity dilemma

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Yale School of Public Health, Department of Epidemiology of Microbial Diseases -FDA EUA summary

Mass screening of asymptomatic persons for SARS-CoV-2 using saliva

Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens

Author Contributions

Alkhateeb: Conceptualization, methodology, formal analysis, investigation, writing -original draft, visualization. Meredith N. Cahill: Formal analysis, resources, data curation, writing -review and editing. Adam S. Ross: Resources, writing -review and editing. Forest W. Arnold: Resources, writingreview and editing. James W. Snyder: Conceptualization, methodology, resources, data curation writingreview and editing, visualization, supervision, project administration. Funding This research did not receive any specific grant from

Alkhateeb: Conceptualization, methodology, formal analysis, investigation, writing -original draft, visualization. Meredith N. Cahill: Formal analysis, resources, data curation, writing -review and editing. Adam S. Ross: Resources, writing -review and editing. Forest W. Arnold: Resources, writingreview and editing. James W. Snyder: Conceptualization, methodology, resources, data curation writingreview and editing, visualization, supervision

We thank the nursing and molecular diagnostics laboratory personnel for their assistance and technical support in collecting some and testing all saliva specimens. We would also like to thank StephenFurmanek for his assistance and guidance with the statistical analysis.

The authors declare no competing financial/non-financial interests.

(3%-60%)

(29%-100%) 100%

(95%-97%)

(68%-100%)

(44%-97%)Late symptomatic (> 4 days) (n=12)

(72% -100%) PPV: Positive predictive value, NPV: Negative predictive value, CI: Confidence interval. * PPV, NPV and accuracy were calculated based on an estimated prevalence of 5%.